NuCana Announces Listing Transfer to Nasdaq Capital Market Edinburgh, United Kingdom

NuCana Announces Listing Transfer to Nasdaq Capital Market

Edinburgh, United Kingdom, November 10, 2023 (GLOBE NEWSWIRE) NuCana plc (NASDAQ: NCNA) ( NuCana or the Company ) announced

today that it has received approval from Listing Qualifications Department of the Nasdaq Stock Market ( Nasdaq ) to transfer the listing of its American Depositary Shares ( ADSs ) from the Nasdaq Global Select Market to the

Nasdaq Capital Market. This transfer became effective at the opening of business on November 9, 2023.

The Nasdaq Capital Market is a continuous

trading market that operates in the same manner as The Nasdaq Global Select Market. Therefore, the Company s ADSs continue to trade under the ticker symbol NCNA and are not affected by this listing transfer. The approval by Nasdaq

was based upon the Company meeting the applicable market value of publicly held shares requirement for continued listing and all other applicable requirements for initial listing on the Nasdaq Capital Market, except for the minimum bid price

In connection with the transfer to the Nasdaq Capital Market, Nasdaq granted the Company an additional

180-day period (or until May 6, 2024) to regain compliance with the requirement set forth in Nasdaq Listing Rule 5450(a)(1) that the bid price of the Company s ADSs meet or exceed $1.00 per ADS for

at least ten consecutive business days. The Company intends to continue actively monitoring the bid price and consider available options to regain compliance with the minimum bid price requirement.

NuCana is a clinical-stage

biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective

and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, they have significant shortcomings that limit their efficacy and they are often poorly tolerated.

Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome the key limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana s

pipeline includes NUC-3373 and NUC-7738. NUC-3373 is a new chemical entity derived from the nucleoside analog 5-fluorouracil, a widely used chemotherapy agent. NUC-3373 is currently being evaluated in three ongoing clinical studies: a Phase 1b/2 study (NuTide:302) in combination with

leucovorin, irinotecan or oxaliplatin, and bevacizumab in patients with metastatic colorectal cancer; a randomized Phase 2 study (NuTide:323) in combination with leucovorin, irinotecan, and bevacizumab for the second-line treatment of patients with

advanced colorectal cancer; and a Phase 1b/2 modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid

tumors and in combination with docetaxel for patients with lung cancer. NUC-7738 is a transformation of 3 -deoxyadenosine, a novel anti-cancer nucleoside analog.

NUC-7738 is in the Phase 2 part of a Phase 1/2 study in patients with advanced solid tumors which is evaluating NUC-7738 as a monotherapy and in combination with

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are

based on the beliefs and assumptions and on information currently available to management of NuCana plc (the Company ). All statements other than statements of historical fact contained in this press release are forward-looking

statements, including statements concerning the Company s current expectations with respect to regaining compliance with Nasdaq listing requirements, the Company s planned and ongoing clinical studies for the Company s product

candidates and the potential advantages of those product candidates, including NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from

and results of those planned and ongoing clinical studies; the Company s goals with respect to the development, regulatory pathway and potential use, if approved, of each of its product candidates; and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as may, will, should,

expects, plans, anticipates, believes, estimates, predicts, potential or continue or the negative of these terms or other comparable terminology.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company s actual results, performance or achievements to be materially different from any future results, performance or achievements

expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the Risk Factors section of the Company s Annual Report on Form 20-F for the year ended December 31, 2022 filed with the Securities and Exchange Commission ( SEC ) on April 4, 2023, and subsequent reports that the Company files with the SEC. Forward-looking

statements represent the Company s beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future

results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the

forward-looking statements to actual results or to changes in its expectations.

For more information, please contact:

Chief Executive Officer